# Dianthus Therapeutics, Inc.: Form 8-K, filed Sep 12, 2023

- Company: [Dianthus Therapeutics, Inc.](/companies/dnth.md) (CIK 1690585)
- Form: 8-K
- Filed: 2023-09-12
- Accepted by EDGAR: Sep 12, 2023, 16:05 ET
- Period: 2023-09-11
- Accession: 0001193125-23-233448
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1690585/000119312523233448/d550960d8k.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1690585/000119312523233448/

## Items reported

- Item 1.01: Entry into a material agreement
- Item 2.01: Completion of an acquisition or disposition
- Item 3.02: Unregistered sale of equity
- Item 3.03: Change to security holders’ rights
- Item 4.01: Change of auditor
- Item 5.01: Change in control
- Item 5.02: Departure or appointment of officers or directors
- Item 5.03: Amendment to articles or bylaws
- Item 5.05: Item not in the standard list
- Item 7.01: Regulation FD disclosure
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1690585/000119312523233448/d550960d8k.htm

Filed Sep 12, 2023.
Source: SEC EDGAR, the filing index for accession 0001193125-23-233448. Last ingested by Listed: Nov 4, 2026, 16:45 ET. No prices; not investment advice.